Onsdag 18 November | 20:05:06 Europe / Stockholm
Est. tid*
2027-01-21 N/A X-dag ordinarie utdelning NEWBRY 0.00 SEK
2027-01-20 N/A Årsstämma
2027-01-20 08:00 Kvartalsrapport 2027-Q1
2026-10-28 - Bokslutskommuniké 2026
2026-07-08 - Kvartalsrapport 2026-Q3
2026-04-15 - Extra Bolagsstämma 2026
2026-04-15 - Kvartalsrapport 2026-Q2
2026-01-21 - Kvartalsrapport 2026-Q1
2026-01-14 - Årsstämma
2026-01-09 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2025-10-29 - Bokslutskommuniké 2025
2025-07-09 - Kvartalsrapport 2025-Q3
2025-04-09 - Kvartalsrapport 2025-Q2
2025-01-24 - Kvartalsrapport 2025-Q1
2025-01-16 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2025-01-15 - Årsstämma
2024-10-23 - Bokslutskommuniké 2024
2024-07-31 - Extra Bolagsstämma 2024
2024-07-10 - Kvartalsrapport 2024-Q3
2024-04-10 - Kvartalsrapport 2024-Q2
2024-01-11 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10 - Årsstämma
2024-01-10 - Kvartalsrapport 2024-Q1
2023-10-11 - Bokslutskommuniké 2023
2023-07-14 - Kvartalsrapport 2023-Q3
2023-04-12 - Kvartalsrapport 2023-Q2
2023-01-12 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 - Årsstämma
2023-01-11 - Kvartalsrapport 2023-Q1
2022-10-13 - Bokslutskommuniké 2022
2022-07-06 - Kvartalsrapport 2022-Q3
2022-04-13 - Kvartalsrapport 2022-Q2
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades 2020 och har sitt huvudkontor i Lund.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Newbury Pharmaceuticals extends and increases loan agreement to SEK 40m, with right to early repayment

2026-11-18 18:25:00

Newbury Pharmaceuticals AB has agreed with AB Slädens Pensionsstiftelse nr 3 to increase the existing loan by SEK 10 million to SEK 40 million and to extend its maturity to 30 June 2028. The amendment also gives Newbury the right to repay the loan early without a prepayment fee. The amendment is subject to approval by the Annual General Meeting on 20 January 2027.

Following approval, the total principal under the loan agreement will be SEK 40 million. The maturity date is extended by 12 months, from 30 June 2027 to 30 June 2028. The interest rate is unchanged at 11% per annum, payable at the end of each quarter. The additional SEK 10 million will be disbursed after approval by the Annual General Meeting. Until then, the existing loan of SEK 30 million continues on its current terms.

The amended agreement gives Newbury the right to repay the loan, in whole or in part, on 30 days’ notice and without any prepayment fee. Newbury intends to refinance parts of the loan with bank financing over time.

In addition, the lender has expressed a non-binding intention to take SEK 10–15 million of the loan as shares instead of cash repayment if Newbury carries out a share issue. The conversion would be made by set-off, on the same terms as for other investors, and would reduce the company’s debt and interest costs. No decision on a share issue has been made, and a conversion would require the approvals applicable at that time.

“This amendment secures the terms of this loan until mid-2028, while the right to early repayment and the lender’s intention to convert part of the loan into equity give us flexibility to reduce our debt over time,” says Karl Karlsson, CEO of Newbury Pharmaceuticals.

The lender, AB Slädens Pensionsstiftelse nr 3, is represented by Johan Orvelin, who is also a member of the Board of Directors of Newbury Pharmaceuticals AB. The transaction has therefore been treated as a related-party transaction. The Board of Directors, with Johan Orvelin recused, has unanimously approved the amendment and concluded that it is on arm’s-length terms and in the best interests of the company and its shareholders. In accordance with good practice on the Swedish stock market, the amendment will be submitted to the Annual General Meeting on 20 January 2027 for approval. The Board’s report on the transaction will be made available ahead of the meeting. No financial advisor has been used, and therefore no transaction costs apply.